Retina

Investigation evaluates safety of single and multiple intravitreal injections.

Understanding nuances of reimbursement for novel, sustained-release ophthalmic drugs can help maximize the opportunity for patients and practice.

The impact of the COVID-19 pandemic on the management of patients with retinal disorders and considerations for how new practices may be adopted into future practice.

Fluorescence lifetime imaging ophthalmoscopy may be useful to monitor the progression of AMD as well as the effectiveness of treatment approaches.

Systemic immunosuppression may prevent devastating complication in patients.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

Dr Mariya Moosajee comments on the next generation of gene therapy for inherited retinal disease and highlights various systems under investigation.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

Long-term treatment helps chronic, vision-threatening disease.

GT005 designed to induce local production of recombinant complement factor I.

Considerations for treating retinal disorders with sustained-release drug delivery implants in an effort to address current treatment challenges in the field.

Ophthalmologists face challenges of drug delivery for retinal diseases.

In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.

Cotargeted therapy could help combat inherited retinal diseases.

Special to Ophthalmology Times®

An overview of delivery systems under investigation for retinal disorders and implications for future use.

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

A discussion highlighting new agents under investigation for retinal disorders and implications for future use based on data revealed in more recent clinical trials.

With at least 24 inherited retinal disease (IRD) clinical trials ongoing in the United States, and additional studies of stem cell therapy in several IRD indications, hope is on the horizon for many patients.

Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.

The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.

Ophthalmologists highlight recent treatment advances in diabetic macular edema and wet age-related macular degeneration.

Outlook Therapeutics has reported positive efficacy and safety data from Phase 3 NORSE TWO trial of bevacizumab-vikg.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.